Capricor Therapeutics Stock Buy Hold or Sell Recommendation
| CAPR Stock | USD 13.23 0.44 3.44% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Capricor Therapeutics is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Capricor Therapeutics within the specified time frame.
Check out Capricor Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide. Note, we conduct extensive research on individual companies such as Capricor and provide practical buy, sell, or hold advice based on investors' constraints. Capricor Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Capricor |
Execute Capricor Therapeutics Buy or Sell Advice
The Capricor recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Capricor Therapeutics. Macroaxis does not own or have any residual interests in Capricor Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Capricor Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Capricor Therapeutics Trading Alerts and Improvement Suggestions
| Capricor Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 25.18 M. Net Loss for the year was (22.29 M) with loss before overhead, payroll, taxes, and interest of (22.13 M). | |
| Capricor Therapeutics currently holds about 51.42 M in cash with (25.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.11. | |
| Capricor Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Capricor Therapeutics Inc Given Average Rating of Buy by Analysts |
Capricor Therapeutics Returns Distribution Density
The distribution of Capricor Therapeutics' historical returns is an attempt to chart the uncertainty of Capricor Therapeutics' future price movements. The chart of the probability distribution of Capricor Therapeutics daily returns describes the distribution of returns around its average expected value. We use Capricor Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Capricor Therapeutics returns is essential to provide solid investment advice for Capricor Therapeutics.
| Mean Return | -0.07 | Value At Risk | -7.53 | Potential Upside | 8.11 | Standard Deviation | 4.55 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Capricor Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Capricor Stock Institutional Investors
The Capricor Therapeutics' institutional investors refer to entities that pool money to purchase Capricor Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Black Diamond Financial, Llc | 2024-12-31 | 277.7 K | Citadel Advisors Llc | 2024-12-31 | 265.2 K | Bank Of America Corp | 2024-12-31 | 170.5 K | Nuveen Asset Management, Llc | 2024-12-31 | 169.1 K | Maven Securities Ltd | 2024-12-31 | 150 K | Kennedy Capital Management Inc | 2024-12-31 | 144.2 K | Rafferty Asset Management, Llc | 2024-12-31 | 126.3 K | Ghost Tree Capital, Llc | 2024-09-30 | 125 K | Ubs Group Ag | 2024-12-31 | 122.8 K | Blackrock Inc | 2024-12-31 | 3 M | Vanguard Group Inc | 2024-12-31 | 2.3 M |
Capricor Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 28.8M | 2.2M | (25.3M) | 5.1M | 5.9M | 6.1M | |
| Free Cash Flow | (10.6M) | (18.0M) | 1.6M | (27.6M) | (24.9M) | (23.6M) | |
| Depreciation | 143.9K | 245.7K | 533.1K | 1.1M | 1.2M | 1.3M | |
| Other Non Cash Items | 325.9K | 129.7K | 196.0K | (18.2K) | (16.4K) | (15.6K) | |
| Net Income | (13.7M) | (20.0M) | (29.0M) | (22.3M) | (20.1M) | (19.1M) | |
| End Period Cash Flow | 32.7M | 34.9M | 9.6M | 14.7M | 16.9M | 17.7M | |
| Change To Inventory | 156.3M | (1.9B) | 391.8M | 0.83 | 0.75 | 0.78 | |
| Change To Netincome | 703.7K | 2.0M | 2.8M | 4.5M | 5.2M | 5.4M | |
| Change Receivables | 116.9K | 88.0K | (391.8K) | (155.8K) | (140.2K) | (133.2K) | |
| Investments | 5.4M | (1.2M) | (31.7M) | 16.1M | 14.5M | 15.2M |
Capricor Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Capricor Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Capricor Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Capricor stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.07 | |
β | Beta against Dow Jones | 1.39 | |
σ | Overall volatility | 4.56 | |
Ir | Information ratio | 0.01 |
Capricor Therapeutics Volatility Alert
Capricor Therapeutics exhibits very low volatility with skewness of 0.24 and kurtosis of 0.1. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Capricor Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Capricor Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Capricor Therapeutics Fundamentals Vs Peers
Comparing Capricor Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Capricor Therapeutics' direct or indirect competition across all of the common fundamentals between Capricor Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Capricor Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Capricor Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Capricor Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Capricor Therapeutics to competition |
| Fundamentals | Capricor Therapeutics | Peer Average |
| Return On Equity | -1.03 | -0.31 |
| Return On Asset | -0.35 | -0.14 |
| Profit Margin | (1.47) % | (1.27) % |
| Operating Margin | (5.75) % | (5.51) % |
| Current Valuation | 518.19 M | 16.62 B |
| Shares Outstanding | 45.47 M | 571.82 M |
| Shares Owned By Insiders | 16.80 % | 10.09 % |
| Shares Owned By Institutions | 38.26 % | 39.21 % |
| Number Of Shares Shorted | 8.16 M | 4.71 M |
| Price To Earning | 42.39 X | 28.72 X |
| Price To Book | 8.81 X | 9.51 X |
| Price To Sales | 25.90 X | 11.42 X |
| Revenue | 25.18 M | 9.43 B |
| Gross Profit | (22.13 M) | 27.38 B |
| EBITDA | (23.01 M) | 3.9 B |
| Net Income | (22.29 M) | 570.98 M |
| Cash And Equivalents | 51.42 M | 2.7 B |
| Cash Per Share | 2.11 X | 5.01 X |
| Total Debt | 2.24 M | 5.32 B |
| Debt To Equity | 0.15 % | 48.70 % |
| Current Ratio | 2.69 X | 2.16 X |
| Book Value Per Share | 1.69 X | 1.93 K |
| Cash Flow From Operations | (25.6 M) | 971.22 M |
| Short Ratio | 8.02 X | 4.00 X |
| Earnings Per Share | (1.02) X | 3.12 X |
| Target Price | 42.43 | |
| Number Of Employees | 101 | 18.84 K |
| Beta | 4.11 | -0.15 |
| Market Capitalization | 601.57 M | 19.03 B |
| Total Asset | 58.73 M | 29.47 B |
| Retained Earnings | (159.37 M) | 9.33 B |
| Working Capital | 19.59 M | 1.48 B |
| Current Asset | 22.4 M | 9.34 B |
Note: Disposition of 750 shares by Collier Earl M Jr of Capricor Therapeutics at 1. subject to Rule 16b-3 [view details]
Capricor Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Capricor . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Capricor Therapeutics Buy or Sell Advice
When is the right time to buy or sell Capricor Therapeutics? Buying financial instruments such as Capricor Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Capricor Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Monster Funds Thematic Idea Now
Monster Funds
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.